Back to search

National and Kapodistrian University of Athens

Μελέτη και κλινική αξιολόγηση δεικτών μεθυλίωσης DNA στον καρκίνο του μαστού

Abstract

dc:description

Epidemiological studies have shown that breast cancer is the second cause of death from malignancy and the first in women between 40-49 years of age. The emerging field of epigenetics revealed that DNA methylation is an important regulator of gene transcription and a large body of evidence has demonstrated that genes with high levels of 5-methylcytosine in their promoter region are transcriptionally silent, and that DNA methylation gradually accumulates upon long-term gene silencing.. Aberrant DNA methylation patterns –compared to normal tissue – have been associated with a large number of human malignancies while methylation may give selective advantage to tumor cells increasing genetic instability and allowing them to metastasize. Abnormal methylation is detectable in early precancerous lesions, suggesting that directly contributes to the malignant transformation of cells and is a late event caused by genetic alterationsIn recent years, the need to identify molecular markers characterized by high sensitivity and specificity in detecting and monitoring early breast cancer has increased. Tumor heterogeneity is one of the major problems limiting the efficacy of targeted therapies and compromising treatment outcomes. Therefore, blood may be a reservoir for collecting DNA from different sources, including CTCs, cfDNA, and occult micrometastatic deposits in secondary organs. As the scope of breast cancer intratumour genetic heterogeneity unravels, analysis of Circulating tumour cells and cell-free plasma DNA contribute for the completion of tumor molecular characterization.Circulating tumor cells (CTCs) are cells that have shed into the vasculature from a primary tumor and circulate in the bloodstream. CTCs thus constitute seeds for subsequent growth of additional tumors (metastasis) in vital distant organs, triggering a mechanism that is responsible for the vast majority of cancerrelated deaths. On the other hand, the presence of extractable amounts of DNA in serum of cancer patients was early identified, suggesting that circulating DNA maybe shed from tumours.In the present phD thesis, we studied DNA methylation of suppressor and metastasis suppressor genes, CST6, SOX17 and BRMS1 developing and applying MSP (Methylation Specific PCR) in primary tumors, cell-free DNA and circulating tumor cells and correlation with clinicopathological features of patients.Firstly, we evaluated the presence of CST6 promoter methylation in cell-free DNA (cfDNA) circulating in plasma of breast cancer patients. CST6 promoter was found highly methylated in cfDNA of breast cancer patients, but not in healthy individuals. CST6 promoter methylation in cfDNA, should be prospectively validated as a novel plasma tumor biomarker for breast cancer in a large cohort of breast cancer patients.We examined for the first time the relationship between epigenetic silencing of BRMS1 and clinical outcome in operable breast cancers and evaluated the expression of BRMS1 protein and BRMS1 methylation status in CTCs using a highly sensitive and specific MSP assay for BRMS1 promoter methylation. Our data show that BRMS1 promoter methylation results in the transcriptional repression of this gene and highlight the potential clinical relevance of this methylation event in operable breast cancer. We show that BRMS1 promoter is methylated in primary tumors of patients with early breast cancer and in corresponding CTC samples but not in noncancerous breast tissues. Additionally, CTCs were highly heterogeneous in respect to BRMS1 expression even in the same patient.Finally we investigated for the first time whether there is a direct connection between the presence of DNA methylation of these three genes in primary tumors and corresponding CTCs and cfDNA in patients with operable breast cancer and verified metastasis. To address this question we have studied DNA methylation of these genes by the same methodology in well characterized matched clinical samples of breast cancer patients. Our results suggest that there is a direct connection between the presence of CTCs and cfDNA in patients with operable breast cancer, after surgical removal of the primary tumor and prove the tumor origin of circulating tumor DNA. The epigenetic characterization of ctDNA has been shown to be a complementary tool with molecular characterization of CTCs for diagnosis, prognosis and management of cancer patients.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Chimonidou, Maria
  • Χειμωνίδου, Μαρία

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44119

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Chimonidou, Maria; Χειμωνίδου, Μαρία. Μελέτη και κλινική αξιολόγηση δεικτών μεθυλίωσης DNA στον καρκίνο του μαστού. National and Kapodistrian University of Athens, 2014. http://hdl.handle.net/10442/hedi/44119